Oncology – Urological
ASCO Guideline Update | Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer
18 Apr, 2023 | 12:54h | UTC
RCT | MRI–guided vs CT–guided stereotactic body radiotherapy for prostate cancer
18 Apr, 2023 | 12:52h | UTC
RCT | Effects of focal vs. extended irreversible electroporation ablation of localized prostate cancer
12 Apr, 2023 | 13:05h | UTCEffect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary on Twitter
Irreversible electroporation (IRE) can provide promising oncological control as a focal therapy for patients with localized low-intermediate risk prostate cancer patients. https://t.co/lmYnYpSRmY
— JAMA Surgery (@JAMASurgery) February 1, 2023
Phase 2 RCT | Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer
10 Apr, 2023 | 13:41h | UTCAddition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
Randomized trial of intermittent hormone therapy +/- radiation to oligometastatic sites of #prostatecancer shows significantly improved PFS & assoc time off hormone therapy & w/normal testosterone from combination. https://t.co/ZnmkQuqHZm #RadOnc #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) April 6, 2023
ESMO Guideline | Updated treatment recommendations for prostate cancer
6 Apr, 2023 | 13:18h | UTC
Guideline | Muscle-invasive and metastatic bladder cancer
6 Apr, 2023 | 13:19h | UTCMuscle-invasive and Metastatic Bladder Cancer – European Association of Urology (see PDF)
RCT | Enzalutamide versus standard antiandrogen therapy in hormone-sensitive prostate cancer with metastasis
5 Apr, 2023 | 13:30h | UTCTestosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
News Release: ENZAMET shows promise as prostate cancer treatment – University of Adelaide
RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer
15 Mar, 2023 | 15:24h | UTCSummary: The article reports on a study that evaluated patient-reported outcomes of 1,643 participants in the ProtecT trial over a period of 7 to 12 years to assess the long-term functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring for localized prostate cancer detected by PSA screening.
The study found that generic quality-of-life scores were similar among the randomized groups over 7 to 12 years. However, although the prostatectomy group had a lower incidence of nocturia, they showed a higher incidence of urinary incontinence and sexual dysfunction compared to the radiotherapy and active monitoring groups. The radiotherapy group had a higher incidence of fecal leakage compared to the other groups.
The study provides evidence that helps patients and their clinicians assess the trade-offs between treatment harms and benefits and make better-informed treatment decisions.
Article: Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment – NEJM Evidence
Original Study: RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
Consensus Statement | Best current practice and research priorities in active surveillance for prostate cancer
15 Mar, 2023 | 15:11h | UTC
Press release | New technique reduces postoperative complications in prostate cancer surgery
14 Mar, 2023 | 13:33h | UTC
Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
14 Mar, 2023 | 13:21h | UTC
RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
13 Mar, 2023 | 15:12h | UTCSummary: The study followed 1643 men diagnosed with localized prostate cancer (diagnosed by screening with PSA) in the United Kingdom between 1999 and 2009 who were randomly assigned to receive active monitoring, prostatectomy, or radiotherapy.
After a median follow-up of 15 years, the study found that while prostatectomy and radiotherapy decreased metastasis, local progression, and the need for long-term androgen deprivation therapy, death from prostate cancer was low regardless of the treatment assigned, with 17 deaths (3.1%) in the active-monitoring group, 12 deaths (2.2%) in the prostatectomy group, and 16 (2.9%) deaths in the radiotherapy group (P=0.53). Additionally, the study found that overall deaths were similar between the groups.
The authors suggest that the choice of therapy for localized prostate cancer involves weighing the benefits and harms associated with each treatment option.
Article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows – University of Bristol
Commentary on Twitter
Presented at #EAU23: In men with prostate cancer on PSA screening, radical treatments led to half the incidence of metastasis and local progression as active monitoring without affecting disease-specific or overall survival (ProtecT trial) https://t.co/G2ABkMkyJg #oncology pic.twitter.com/s2Va08Fpxj
— NEJM (@NEJM) March 11, 2023
RCT/extended follow-up | Lenvatinib plus pembrolizumab vs. sunitinib in patients with advanced renal cell carcinoma
9 Mar, 2023 | 14:03h | UTCLenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study – The Lancet Oncology (link to abstract – $ for full-text)
Original Study: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW: In extended FU of the CLEAR trial (+7 mo), median PFS was 23·3 mo (95% CI 20·8–27·7) with first-line lenvatinib + pembrolizumab and 9·2 mo (6·0–11·0) with sunitinib (stratified HR 0·42, 95% CI 0·34–0·52) in pts w/ advanced renal cell carcinoma. #rccsmhttps://t.co/gbwBIIqSK8 pic.twitter.com/78OijM9Rtm
— The Lancet Oncology (@TheLancetOncol) February 28, 2023
Consensus Paper | Management of patients with advanced prostate cancer
7 Mar, 2023 | 13:02h | UTC
Guideline | Diagnosis, management, and follow-up of the incidentally discovered adrenal mass
6 Mar, 2023 | 14:16h | UTC
RCT | Temporary cessation vs. continuation of first-line tyrosine kinase inhibitor in advanced clear cell renal cell carcinoma
22 Feb, 2023 | 12:40h | UTCSummary: The STAR trial investigated whether a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma. All patients received standard dosing schedules of oral sunitinib (50 mg per day) or oral pazopanib (800 mg per day) for 24 weeks before moving into their randomly allocated group. Although non-inferiority could not be concluded for the primary endpoint of overall survival, temporary treatment cessation was found to preserve quality of life and was cost-effective. Therefore, planned breaks in tyrosine kinase inhibitor treatment represent a reasonable option for selected patients with renal cell carcinoma, providing potential lifestyle and health economic benefits. The study provides a rationale for further exploration of treatment breaks in patients with other cancers.
Commentary on Twitter
NOW OF: The STAR open-label ph 2/3 RCT could not conclude that a TKI drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma. #rccsmhttps://t.co/xzCU1jdLE7 pic.twitter.com/Ks1Eh0vMId
— The Lancet Oncology (@TheLancetOncol) February 14, 2023
RCT | Rucaparib vs. physician’s choice in metastatic prostate cancer
20 Feb, 2023 | 12:17h | UTCSummary: This phase 3 randomized trial compared Rucaparib vs. physician’s choice control (docetaxel or a second-generation ARPI) in treating metastatic, castration-resistant prostate cancer patients with a BRCA1, BRCA2, or ATM alteration who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). The study found that the duration of radiographic progression-free survival was significantly longer in the rucaparib group than in the control group. The most frequent adverse events with rucaparib were fatigue and nausea.
Article: Rucaparib or Physician’s Choice in Metastatic Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer – HealthDay
Commentary on Twitter
Original Article: Rucaparib or Physician’s Choice in Metastatic Prostate Cancer (TRITON3) https://t.co/vuHTxqRRyb#GU23 #oncology pic.twitter.com/UrPMOgW4Fo
— NEJM (@NEJM) February 17, 2023
RCT | Adjuvant nivolumab plus ipilimumab not better than placebo for localized renal cell carcinoma after nephrectomy
16 Feb, 2023 | 15:15h | UTCAdjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
RCT | Hyaluronic acid spacer for hypofractionated prostate radiation therapy
13 Feb, 2023 | 12:25h | UTC
Commentary on Twitter
Multicenter randomized clin trial in prostate cancer tested presence or absence of hyaluronic acid rectal spacer before receiving hypofractionated radiation, showed acute grade >2 GI toxicity in 2.9% of pts w/spacer vs. 13.8% in control group #PCSM #RadOnc https://t.co/eTifx0b1x2
— JAMA Oncology (@JAMAOnc) February 9, 2023
Guideline | Management of metastatic castration-naive and castration-sensitive prostate cancer
23 Jan, 2023 | 13:33h | UTC2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer – Canadian Urological Association Journal (PDF here)
See also: Summary of changes (PDF here)
CanRisk-Prostate | A comprehensive, externally validated risk model for the prediction of future prostate cancer
20 Jan, 2023 | 14:22h | UTCCommentary: Risk Model for Predicting the Development of Prostate Cancer – The ASCO Post
News Release: Prostate cancer risk prediction algorithm could help target testing at men at greatest risk – University of Cambridge
Consensus Statement | Management of patients with advanced prostate cancer
18 Jan, 2023 | 14:26h | UTC
RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer
15 Jan, 2023 | 20:05h | UTC
Commentary from the author on Twitter (thread – click for more)
Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology https://t.co/5ZKElUR4uk (1/n)
— Amar Kishan (@AmarUKishan) January 12, 2023
Cohort Study | 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma
11 Jan, 2023 | 14:10h | UTC5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
?1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect for 50-day link: #radonc #kcsm https://t.co/kCM8TraJE3
— Shankar Siva (@_ShankarSiva) November 16, 2022
Review | Advances in diagnosis and treatment of testicular cancer.
16 Dec, 2022 | 13:25h | UTCAdvances in diagnosis and treatment of testicular cancer – The BMJ